Sprout Pharmaceuticals, Inc.
Flibanserin, an oral pharmaceutical therapeutic for hypoactive sexual desire disorder (HSDD) in women
Follows are private to you and power your alerts
Updated · sproutpharmaceuticals.com
- Sector
- Biotech
- Headquarters
- RALEIGH, NC
- Founded
- 2011
- Latest Form D
- $50M, Jun 2015
- Total capital
- $81.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $81.7M
- 5 Form D · last Jun 2015
- 137 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 15
- 25 pending · first 2016
- Rank in peer group#112 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$50M
- Private capital raisedForm D · SEC · 4th filing$4.3M
- Private capital raisedForm D · SEC · 3rd filing$4.8M
- Private capital raisedForm D · SEC · 2nd filing$17.6M
- Private capital raisedForm D · SEC · 1st filing$5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#112 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anne S. TomalinExecutive OfficerNamed in SEC Form D filings
- Anthony Robert WildDirectorNamed in SEC Form D filings
- Braxton Robert GoodrichDirectorNamed in SEC Form D filings
- Cynthia S. WhiteheadExecutive OfficerNamed in SEC Form D filings
- Douglas W. EckertExecutive Officer, DirectorNamed in SEC Form D filings
- Fred S. PrudenExecutive OfficerNamed in SEC Form D filings
Show all 17 people
- James S PrudenExecutive OfficerNamed in SEC Form D filings
- James Robert SymonsExecutive OfficerNamed in SEC Form D filings
- Josephine S. TorrenteExecutive OfficerNamed in SEC Form D filings
- Matthew S. PetzoldExecutive OfficerNamed in SEC Form D filings
- Michael Robert FordDirectorNamed in SEC Form D filings
- Richard Robert DeSchutterDirectorNamed in SEC Form D filings
- Rich S. FrancoExecutive OfficerNamed in SEC Form D filings
- Robert W. DahlDirectorNamed in SEC Form D filings
- Robert S. WhiteheadExecutive Officer, DirectorNamed in SEC Form D filings
- Trygve Robert MikkelsenDirectorNamed in SEC Form D filings
- W. Robert DahlDirectorNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 40- PendingTreating Sexual Desire Disorders With FlibanserinUSPTOApplication 17351854
- GrantedTreating Sexual Desire Disorders With FlibanserinUSPTOUS 11,058,683
- PendingUse Of Flibanserin In The Treatment Of ObesityUSPTOApplication 17101961
Show all 40 patent records
- Treating Sexual Desire Disorders With FlibanserinOct 7, 2021 · Application 17351854Pending
- Treating Sexual Desire Disorders With FlibanserinJul 13, 2021 · US 11,058,683Granted
- Use Of Flibanserin In The Treatment Of ObesityMar 11, 2021 · Application 17101961Pending
- Use Of Flibanserin In The Treatment Of ObesityDec 29, 2020 · US 10,874,668Granted
- Treatment Of Vasomotor SymptomsAug 13, 2020 · Application 16810273Pending
- Treating Sexual Desire Disorders With FlibanserinJun 9, 2020 · US 10,675,280Granted
- Treatment of Vasomotor SymptomsMar 24, 2020 · US 10,596,170Granted
- Use of Flibanserin in the Treatment of ObesityJul 2, 2019 · US 10,335,407Granted
- Treating Sexual Desire Disorders with FlibanserinJun 4, 2019 · US 10,307,420Granted
- Treatment of Vasomotor SymptomsJan 1, 2019 · US 10,166,230Granted
- Treating Sexual Desire Disorders with FlibanserinOct 16, 2018 · US 10,098,876Granted
- Flibanserin for the Treatment of Urinary Incontinence and Related DiseasesJun 26, 2018 · US 10,004,731Granted
- Treatment of Vasomotor SymptomsApr 24, 2018 · US 9,949,969Granted
- Treating Sexual Desire Disorders with FlibanserinOct 10, 2017 · US 9,782,403Granted
- Flibanserin for the Treatment of Urinary Incontinence and Related DiseasesSep 19, 2017 · US 9,763,936Granted
- Use of Flibanserin in the Treatment of ObesityAug 15, 2017 · US 9,730,927Granted
- SaltsJan 17, 2017 · US 9,546,141Granted
- Treating Sexual Desire Disorders with FlibanserinOct 18, 2016 · US 9,468,639Granted
- Use Of A Polymorph Of Flibanserin For Treating DiseaseApr 7, 2016 · Application 14876235Pending
- Pharmaceutical compositions containing flibanserinApr 7, 2016 · Application 14867779Pending
- Use of Flibanserin for the Treatment of Post-Menopausal Sexual Desire DisordersDec 31, 2015 · Application 14702125Pending
- Use of flibanserin for the treatment of pre-menopausal sexual desire disordersDec 24, 2015 · Application 14665083Pending
- Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor AffinityDec 24, 2015 · Application 14690981Pending
- Pharmaceutical Compositions for the Treatment of Sexual Disorders IINov 12, 2015 · Application 14656877Pending
- Use of Flibanserin for the Treatment of Sexual Disorders in FemalesAug 27, 2015 · Application 14583292Pending
- Formulations Of FlibanserinAug 13, 2015 · Application 14570467Pending
- Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual DisordersJun 11, 2015 · Application 14519374Pending
- Method Of Using Flibanserin For NeuroprotectionFeb 26, 2015 · Application 14319420Pending
- Use of Flibanserin for the Treatment of Post-Menopausal Sexual Desire DisordersFeb 19, 2015 · Application 14313291Pending
- Treating Sexual Desire Disorders with FlibanserinJan 8, 2015 · Application 14269373Pending
- Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor AffinityJan 8, 2015 · Application 14273126Pending
- Use Of A Polymorph Of Flibanserin For Treating DiseaseJan 1, 2015 · Application 14269420Pending
- Pharmaceutical compositions containing flibanserinJan 1, 2015 · Application 14269468Pending
- Use of flibanserin for the treatment of pre-menopausal sexual desire disordersNov 6, 2014 · Application 14196431Pending
- Treating Sexual Desire Disorders with FlibanserinFeb 27, 2014 · Application 13920354Pending
- Method Of Using Flibanserin For NeuroprotectionFeb 13, 2014 · Application 13906766Pending
- Use Of A Polymorph Of Flibanserin For Treating DiseaseJan 30, 2014 · Application 13905709Pending
- Pharmaceutical compositions containing flibanserinJan 9, 2014 · Application 13863566Pending
- Treatment of Vasomotor SymptomsJan 2, 2014 · Application 13847683Pending
- Use of flibanserin for the treatment of pre-menopausal sexual desire disordersAug 29, 2013 · Application 13675164Pending
Related companies, and why
- Chirality Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Anodyne Nanotech, Inc.Similar federal contract value in Biotech · null in contracts
- Ember Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Vaginal Biome Science, Inc.Similar federal contract value in Biotech · null in contracts
- WPD Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Plowshare Therapies LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .